LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
HYMPAVZI’s safety profile was generally favorable
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Jaypirca is making waves in the fight against B-cell malignancies
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Subscribe To Our Newsletter & Stay Updated
